-
公开(公告)号：US10449231B2
公开(公告)日：2019-10-22
申请号：US15492981
申请日：2017-04-20
Applicant: Takeda Vaccines, Inc. , THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventor： Dan T. Stinchcomb , Claire Kinney , Richard M. Kinney , Jill A. Livengood
IPC: A61K39/12 , C12N15/09 , A61K38/16 , A61K31/713 , C07K14/005 , A61K31/7048 , C07K14/18 , C07K19/00 , C12N15/861 , A61K39/00 , A61P31/14
Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
-
公开(公告)号：US09890362B2
公开(公告)日：2018-02-13
申请号：US14491805
申请日：2014-09-19
Applicant: Takeda Vaccines, Inc.
Inventor： Dan T Stinchcomb , Jill A. Livengood , O'Neil Wiggan , Richard Kinney , Jorge Osorio
CPC classification number: C12N7/00 , C12N2770/24134 , C12N2770/24151
Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
-
公开(公告)号：US11975062B2
公开(公告)日：2024-05-07
申请号：US16768499
申请日：2018-11-30
Applicant: Takeda Vaccines, Inc.
Inventor： Jill A. Livengood , Hansi Dean , Htay Htay Han , Raman Rao , Jackie Marks , Gary Dubin , Laurence De Moerlooze , Hetal Patel , Asae Shintani , Holli Giebler , James Gifford , Mark Lyons , Sushma Kommareddy , Tatsuki Satou
CPC classification number: A61K39/12 , A61P31/14 , C12N7/00 , C12Q1/22 , A61K2039/5252 , A61K2039/545 , C12N2770/24134 , C12N2770/24151 , C12N2770/24163 , G01N30/74
Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
-
公开(公告)号：US20180251737A1
公开(公告)日：2018-09-06
申请号：US15856770
申请日：2017-12-28
Applicant: Takeda Vaccines, Inc.
Inventor： Dan T. Stinchcomb , Jill A. Livengood , O'Neil Wiggan , Richard Kinney , Jorge Osorio
IPC: C12N7/00
CPC classification number: C12N7/00 , C12N2770/24134 , C12N2770/24151
Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
-
公开(公告)号：US12186363B2
公开(公告)日：2025-01-07
申请号：US17478537
申请日：2021-09-17
Applicant: TAKEDA VACCINES, INC. , THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
Inventor： Dan T. Stinchcomb , Claire Kinney , Richard M. Kinney , Jill A. Livengood
IPC: A61K39/12 , A61K31/7048 , A61K31/713 , A61K38/16 , C07K14/005 , C07K14/18 , C07K19/00 , C12N15/09 , C12N15/861 , A61K39/00 , A61P31/14
Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
-
Patent Agency Ranking
公开(公告)号：US11931399B2
公开(公告)日：2024-03-19
申请号：US18064775
申请日：2022-12-12
Applicant: TAKEDA VACCINES, INC.
Inventor： Dan T. Stinchcomb , Claire Kinney , Richard M. Kinney , Jill A. Livengood
IPC: A61K39/12 , A61K31/7048 , A61K31/713 , A61K38/16 , C07K14/005 , C07K14/18 , C07K19/00 , C12N15/09 , C12N15/861 , A61K39/00 , A61P31/14
CPC classification number: A61K38/162 , A61K31/7048 , A61K31/713 , A61K39/12 , C07K14/005 , C07K14/1825 , C07K19/00 , C12N15/09 , C12N15/8613 , A61K2039/5254 , A61K2039/70 , A61P31/14 , C07K2319/00 , C12N2770/24122 , C12N2770/24134 , C12N2770/24141 , C12N2770/24143 , C12N2770/24162 , Y02A50/30
Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
-
公开(公告)号：US11648304B2
公开(公告)日：2023-05-16
申请号：US16761368
申请日：2018-11-05
Applicant: TAKEDA VACCINES, INC. , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventor： Jill A. Livengood , Holli Giebler , Whitney Baldwin , Hansi Dean , Claire Y. H. Kinney
CPC classification number: A61K39/12 , A61K9/0019 , A61K39/39 , A61P31/14 , C12N7/00 , A61K2039/5252 , A61K2039/54 , A61K2039/545 , A61K2039/55505 , C12N2770/24034 , C12N2770/24071 , C12N2770/24134 , C12N2770/24151 , C12N2770/24163 , C12N2770/24164
Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.
-
公开(公告)号：US10898565B2
公开(公告)日：2021-01-26
申请号：US15996275
申请日：2018-06-01
Applicant: Takeda Vaccines, Inc , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES
Inventor： Jill A. Livengood , Claire Kinney , Timothy D. Powell , Dan T. Stinchcomb , Jorge Osorio
Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
-
公开(公告)号：US10806781B2
公开(公告)日：2020-10-20
申请号：US16159221
申请日：2018-10-12
Applicant: Takeda Vaccines, Inc.
Inventor： Dan T. Stinchcomb , Jill A. Livengood , Laszlo Varga
Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
-
公开(公告)号：US20240216498A1
公开(公告)日：2024-07-04
申请号：US18523331
申请日：2023-11-29
Applicant: Takeda Vaccines, Inc.
Inventor： Joseph David Santangelo , Jill A. Livengood , Yock Ann Lee , Weiwen Luo
CPC classification number: A61K39/12 , A61K9/19 , C12N7/00 , A61K2039/5254 , C12N2770/24122 , C12N2770/24134 , C12N2770/24152 , C12N2770/24162
Abstract: The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.022 seconds)
